Phase Ib/II Trial of Sonrotoclax and BCMA Bispecific Antibody in Systemic AL Amyloidosis
A phase Ib/II trial is evaluating sonrotoclax plus dexamethasone in newly diagnosed systemic AL amyloidosis patients based on t(11;14) genetic stratification.
Phase III
Hematology / Systemic AL Amyloidosis
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing phase Ib/II trial of sonrotoclax in systemic AL amyloidosis could redefine treatment paradigms for this niche patient population. Positive outcomes may lead to significant shifts in competitive dynamics within the hematology sector, particularly for therapies targeting similar indications.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include the determination of the recommended phase II dose and safety results from the trial.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.